JP7198221B2 - 抗癌化合物 - Google Patents

抗癌化合物 Download PDF

Info

Publication number
JP7198221B2
JP7198221B2 JP2019556888A JP2019556888A JP7198221B2 JP 7198221 B2 JP7198221 B2 JP 7198221B2 JP 2019556888 A JP2019556888 A JP 2019556888A JP 2019556888 A JP2019556888 A JP 2019556888A JP 7198221 B2 JP7198221 B2 JP 7198221B2
Authority
JP
Japan
Prior art keywords
cancer
formula
compound
added
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519568A5 (enExample
JP2020519568A (ja
Inventor
ヴィッタール ヤダフ
マイティリ アタヴァレ
プラシャント カーカル
サンギータ スリヴァスタヴァ
サミール ソマイヤ
スメラ サティッシュ
サンディップ ガヴァデ
Original Assignee
ゴーダーヴァリ バイオリファイナリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴーダーヴァリ バイオリファイナリーズ リミテッド filed Critical ゴーダーヴァリ バイオリファイナリーズ リミテッド
Publication of JP2020519568A publication Critical patent/JP2020519568A/ja
Publication of JP2020519568A5 publication Critical patent/JP2020519568A5/ja
Application granted granted Critical
Publication of JP7198221B2 publication Critical patent/JP7198221B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/44—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3
    • C07D311/46—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring
    • C07D311/48—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring with two such benzopyran radicals linked together by a carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/56—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019556888A 2017-04-20 2018-04-19 抗癌化合物 Active JP7198221B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201621035967 2017-04-20
IN201621035967 2017-04-20
IN201721045003 2017-12-14
IN201721045003 2017-12-14
PCT/IN2018/050237 WO2018193476A2 (en) 2017-04-20 2018-04-19 Anticancer compounds

Publications (3)

Publication Number Publication Date
JP2020519568A JP2020519568A (ja) 2020-07-02
JP2020519568A5 JP2020519568A5 (enExample) 2021-05-27
JP7198221B2 true JP7198221B2 (ja) 2022-12-28

Family

ID=62244517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556888A Active JP7198221B2 (ja) 2017-04-20 2018-04-19 抗癌化合物

Country Status (5)

Country Link
US (2) US11084843B2 (enExample)
EP (1) EP3612172B1 (enExample)
JP (1) JP7198221B2 (enExample)
ES (1) ES3030482T3 (enExample)
WO (1) WO2018193476A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3050624T3 (en) * 2018-12-17 2025-12-22 Godavari Biorefineries Ltd Compounds for the inhibition of unregulated cell growth
JP2023525103A (ja) * 2020-05-11 2023-06-14 ゴーダーヴァリ バイオリファイナリーズ リミテッド ウイルス感染の治療のための化合物の使用
CA3232832A1 (en) * 2021-09-22 2023-03-30 Godavari Biorefineries Limited Pharmaceutical composition and a process to prepare the same

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101463055A (zh) 2009-01-15 2009-06-24 天津药物研究院 一类o-糖苷化合物、其制备方法和用途
WO2012081038A2 (en) 2010-12-17 2012-06-21 Godavari Biorefineries Limited Anticancer compounds and targeting cancer with the same
JP2012516886A (ja) 2009-02-05 2012-07-26 ゴーダーヴァリ バイオリファイナリーズ リミテッド クレイスタンチンの製造方法
WO2012099247A1 (ja) 2011-01-21 2012-07-26 花王株式会社 美白剤
CN103467463A (zh) 2013-09-18 2013-12-25 南开大学 一类木脂素类衍生物及其制备方法和用途
WO2015002038A1 (ja) 2013-07-01 2015-01-08 株式会社トクヤマ 新規なフェニルナフトール誘導体
CN104844614A (zh) 2015-03-31 2015-08-19 华东师范大学 奥托肉豆蔻脂素化合物及制备方法和用途
WO2015153653A1 (en) 2014-03-31 2015-10-08 Ohio State Innovation Foundation Arylnaphthalene lactone derivatives and methods of making and using thereof
JP2016503005A (ja) 2012-12-18 2016-02-01 ゴーダーヴァリ バイオリファイナリーズ リミテッド 腫瘍始原細胞を除去するための薬剤
US20160068490A1 (en) 2014-08-14 2016-03-10 Rigel Pharmaceuticals, Inc. Ubiquitination inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101463055A (zh) 2009-01-15 2009-06-24 天津药物研究院 一类o-糖苷化合物、其制备方法和用途
JP2012516886A (ja) 2009-02-05 2012-07-26 ゴーダーヴァリ バイオリファイナリーズ リミテッド クレイスタンチンの製造方法
WO2012081038A2 (en) 2010-12-17 2012-06-21 Godavari Biorefineries Limited Anticancer compounds and targeting cancer with the same
WO2012099247A1 (ja) 2011-01-21 2012-07-26 花王株式会社 美白剤
JP2016503005A (ja) 2012-12-18 2016-02-01 ゴーダーヴァリ バイオリファイナリーズ リミテッド 腫瘍始原細胞を除去するための薬剤
WO2015002038A1 (ja) 2013-07-01 2015-01-08 株式会社トクヤマ 新規なフェニルナフトール誘導体
CN103467463A (zh) 2013-09-18 2013-12-25 南开大学 一类木脂素类衍生物及其制备方法和用途
WO2015153653A1 (en) 2014-03-31 2015-10-08 Ohio State Innovation Foundation Arylnaphthalene lactone derivatives and methods of making and using thereof
US20160068490A1 (en) 2014-08-14 2016-03-10 Rigel Pharmaceuticals, Inc. Ubiquitination inhibitors
CN104844614A (zh) 2015-03-31 2015-08-19 华东师范大学 奥托肉豆蔻脂素化合物及制备方法和用途

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
HORII, Zen-ichi; et al，Chem.Pharm.Bull.，1977年，25(7)，1803-1808
HUI, Jie ; ET AL，MEDICINAL CHEMISTRY RESEARCH，2011年12月23日，21(12)，3994 - 4001，http://dx.doi.org/10.1007/s00044-011-9937-1
NARESH, Gunaganti; et al，Organic Letters，2015年，17，3446-3449
POHL, Radek; et al，J.Org.Chem.，2004年，69，1723-1725
RAGHAVENDRA, Kanchipura Ramachandrappa; et al，Der Pharma Chemica，2015年，7(7)，153-160
RAGHAVENDRA,K.R.; et al，Journal of Chemical and Pharmaceutical Research，2015年，7(8)，638-644
SARGENTI, Azzurra; et al，Nature Protocols，2017年，12(3)，461-471
SINGH, Rajinder; ET AL，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，2015年09月30日，25(22)，5199 - 5202，http://dx.doi.org/10.1016/j.bmcl.2015.09.067
SUBBARAJU, Gottumukkala V. ; ET AL，INDIAN JOURNAL OF CHEMISTRY，2001年04月，40B，313 - 319，http://nopr.niscair.res.in/bitstream/123456789/22309/1/IJCB%2040B(4)%20313-319.pdf
TUCHUNDA, Patoomratana ; et al，PLANTA MEDICA，2006年，72(1)，60-62
VENKATESWARLU, R.; et al，Tetrahedron，2006年，62，4463-4473
WANG, Ying ; ET AL，CHEMICAL BIOLOGY & DRUG DESIGN，2016年10月，88(4)，562 - 567，http://dx.doi.org/10.1111/cbdd.12785
WOLF, Christian; et al，Journal of Chromtography A，1997年，785，173-178
YOUSSEF, D.T.A.，Bulletin of Pharmaceutical Sciences, Assiut University，2005年，28(2)，261-267
ZHAO, Yu; et al，BIOORGANIC & MEDICINAL CHEMISTRY，2015年05月27日，23，4884-4890
ZHAO, Yu; ET AL，CHINESE JOURNAL OF APPLIED CHEMISTRY (Yingyong Huaxue)，2008年11月01日，25(11)，1315-1319
ZHAO, Yu; ET AL，MEDICINAL CHEMISTRY RESEARCH，2013年05月，22(5)，2505 - 2510，http://dx.doi.org/10.1007/s00044-012-0245-1

Also Published As

Publication number Publication date
US11084843B2 (en) 2021-08-10
EP3612172C0 (en) 2025-04-09
WO2018193476A2 (en) 2018-10-25
US20220389046A1 (en) 2022-12-08
EP3612172B1 (en) 2025-04-09
US20190284222A1 (en) 2019-09-19
EP3612172A2 (en) 2020-02-26
WO2018193476A3 (en) 2019-01-03
JP2020519568A (ja) 2020-07-02
US11680078B2 (en) 2023-06-20
ES3030482T3 (en) 2025-06-30

Similar Documents

Publication Publication Date Title
JP2016503005A (ja) 腫瘍始原細胞を除去するための薬剤
CA2854836C (en) Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
US11680078B2 (en) Anticancer compounds
CA2901155C (en) Camkii inhibitors and uses thereof
EP3189052B1 (en) Camkii inhibitors and uses thereof
US10682367B2 (en) Antitumor arylnaphthalene ligand glycosides
JP7536016B2 (ja) 無制御細胞成長の阻害用の化合物
WO2012081038A2 (en) Anticancer compounds and targeting cancer with the same
JP2023550014A (ja) がんの治療に使用するための５－ヒドロキシ－１，４－ナフタレンジオン
JP2017506617A (ja) 未制御細胞成長の阻害のための化合物
US20250289837A1 (en) Mitochondriotropic heteroaryl benzamide potassium channel kv1.3 inhibitors
WO2012081039A1 (en) Molecules with anticancer activity and uses thereof
EA042939B1 (ru) Ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200519

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210413

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221216

R150 Certificate of patent or registration of utility model

Ref document number: 7198221

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250